Newsfeeds - Spark Newswire

1 minute read

Evogene Subsidiary Lavie Bio Announces Advancement In Its Bio-Fungicide Program For Fruit Rots

Today, 5:50 PM

Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd.

EVGN

10 minute read

The Week In Cannabis: Stocks Down, Republican Legalization Bill, Germany, Uruguay, Earnings, New ETF And More

By Javier Hasse

Today, 5:50 PM

Below is a recap of the main news related to the cannabis industry and markets for the week of November 15, 2021. Contents

ACB

1 minute read

Evogene Q3 EPS $(0.19) Misses $(0.17) Estimate, Sales $151.00K Miss $270.00K Estimate

By Bill Haddad

Today, 5:50 PM

Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 11.76 percent decrease over losses of $(0.17) per share from the

EVGN

5 minute read

Earnings Scheduled For November 17, 2021

By Benzinga Insights

Today, 5:50 PM

Companies Reporting Before The Bell • ZIM Integrated Shipping (NYSE:ZIM) is projected to report quarterly earnings at $9.25 per share on revenue of $2.77 billion.

ASYS

3 minute read

News

Evogene Subsidiary Lavie Bio Highlights Commercial Launch Of Its First Product, LAV.211, An Inoculant For Yield Improvement, Under The Brand Name ‘result’

By Benzinga Newsdesk

Today, 5:50 PM

Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction

EVGN

2 minute read

Evogene’s Canonic Launches First Two Medical Cannabis Products In Israel Ahead Of Schedule

By Jelena Martinovic

Today, 5:50 PM

Evogene Ltd.'s (NASDAQ: EVGN) (TASE: EVGN) wholly-owned subsidiary focused on developing medical cannabis products, Canonic Ltd., announced the full commercial launch of its first two medical cannabis inflorescence products, known as G200 and G150.

EVGN

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 8, 2021

By Benzinga Insights

Today, 5:50 PM

Upgrades

ALLE

1 minute read

Roth Capital Initiates Coverage On Evogene with Buy Rating, Announces Price Target of $7

By Benzinga Newsdesk

Today, 5:50 PM

Roth Capital initiates coverage on Evogene (NASDAQ:EVGN) with a Buy rating and announces Price Target of $7.

EVGN

9 minute read

The Week In Cannabis: An Earnings Avalanche, Biden’s Clemency Plans, Cuomo’s Resignation And More

By Javier Hasse

Today, 5:50 PM

Below is a recap of the main news related to the cannabis industry and markets for the week of August 13, 2021, which was marked by earnings reports out of many of the largest companies in the space – all details below.

AAWH

2 minute read

Evogene Reports $135.000 In Q2 2021 Revenue, Misses Estimates, EPS Beat Projections By $0.02

By Jelena Martinovic

Today, 5:50 PM

Biotechnology company Evogene Ltd.

EVGN